Sector News

The U.K. is open for biotech business, and Merck is buying in

November 20, 2014
Life sciences
The U.K. is striving to brand itself as a hotbed for biotech R&D, promising new funds for startups, pledging to speed up its approval process and courting some major players to deepen their roots in the country.
 
Following through on Prime Minister David Cameron’s 2011 pledge to make the U.K. a global life sciences hub, local leaders have set out a welcome mat for industry, securing a major commitment from Merck in the process. The U.S. pharma giant has pledged to invest at least £42 million ($66 million) in the country over the next three years as it blueprints a London dealmaking outpost. Merck also intends to expand its R&D operations in Hertfordshire, focusing on oncology and dementia research, the company said.
 
The unveiling of Merck’s investment is part of a coordinated attention grab on the part of the British government, which is also touting an expansion of its Biomedical Catalyst program, through which Innovate UK and the Medical Research Council bankroll startups and academic-led R&D projects with commercial potential. The two organizations have earmarked another £31 million ($49 million) for the program, piling onto the £200 million ($314 million) they’ve already awarded to more than 250 companies.
 
And, beyond supporting the development of new treatments, the U.K. says it wants to help get them to patients faster. In response to long-levied criticisms of how long it takes for new drugs to reach British shores, the government is plotting an Innovative Medicines Review, which will examine how regulators can work with industry to more quickly get the most promising treatments into use within the country’s National Health Service.
 
The news was well-received by U.K. industry groups, which have for years lobbied the government to help inculcate a life sciences hub like the one in Boston, where world-class research institutions abut promising biotech startups and Big Pharma recon squads.
 
Stephen Whitehead, CEO of the Association of the British Pharmaceutical Industry, praised the effort as a welcome response to “increasing evidence of the need for a holistic approach to U.K. life sciences,” at the same time challenging the government to loosen up its strict cost-effectiveness rules for new drugs. Steve Bates, chief of the nation’s BioIndustry Association, heralded the government’s work as “crucial to the success of the U.K. life science ecosystem” and key to his organization’s ambitions of creating a booming biotech home base.
 
That promise was particularly alluring to Merck, company Global Human Health President Adam Schechter said, and the drugmaker sees a bright future for itself in the U.K.’s interconnected research community.
 
“We are impressed with the United Kingdom’s approach to its Life Sciences strategy which takes an ‘end to end’ view of medicines, from discovery through their use in the real world,” Schechter said in a statement. “Our commitment extends beyond the realms of academic and clinical research, and strives to find innovative ways to use data and technology to transform healthcare and in turn, patients’ lives.”
 
The nation’s biopharma R&D scene is on the mend after years of cutbacks and site closures from the likes of Pfizer, AstraZeneca and Shire. Many of the U.K.’s largest drug developers have gradually abandoned far-flung corporate campuses in favor of more urban outposts within the triangle of London, Cambridge and Oxford, a trend leaders public and private hope will help foster a return to growth.
 
By Damian Garde
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend